Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Harnessing Endogenous Regulators Against CLE Study

Next Previous
Trial Profile

Harnessing Endogenous Regulators Against CLE Study

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SOF SKN (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Acronyms HERACLES

Most Recent Events

  • 02 May 2025 According to a Noxopharm media release, company has applied for Human Research Ethics Committee (HREC) approval for the HERACLES clinical trial.
  • 15 Apr 2025 According to a Noxopharm media release, the next milestone for the company is to apply for Human Research Ethics Committee (HREC) approval for the clinical trial, which will be the finalregulatory step before HERACLES can commence.
  • 12 Mar 2025 According to a Noxopharm media release, trial will take place in Melbourne and will be conducted by Doherty Clinical Trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top